The present study reveals the selective chemotherapeutic efficacy of THZ531 in MYC-high MB, thus further highlighting the importance to diversify the treatments on the basis of the genomic and molecular profiles of the tumour, as already in use for other cancer types (i.e. breast and colon cancers). This evidence concerns the gene MYC and cancer.